David Dreyfus, DBA

home / authors / david-dreyfus-dba

Articles

May 3rd 2016

Costs and Spillover Effects of Private Insurers' Coverage of Hepatitis C Treatment

Gigi A. Moreno, PhD Karen Mulligan, PhD Caroline Huber, MPH Mark T. Linthicum, MPP David Dreyfus, DBA Timothy Juday, PhD Steven E. Marx, PharmD Yuri Sanchez Gonzalez, PhD Ron Brookmeyer, PhD Darius N. Lakdawalla, PhD

Expanding private-payer coverage of hepatitis C treatment may yield significant long-term cost savings for private payers, reduced costs to Medicare, and increased social value.

May 3rd 2016

Value of Expanding HCV Screening and Treatment Policies in the United States

Mark T. Linthicum, MPP Yuri Sanchez Gonzalez, PhD Karen Mulligan, PhD Gigi A. Moreno, PhD David Dreyfus, DBA Timothy Juday, PhD Steven E. Marx, PharmD Darius N. Lakdawalla, PhD Brian R. Edlin, MD Ron Brookmeyer, PhD

Expanding screening for hepatitis C virus infection may generate substantial benefits for patients and society, but only when paired with expanded treatment policies.